Summary: A partnership between Revvity and Genomics England seeks to enhance genomic research, focusing on early detection of rare genetic conditions in newborns through its Generation Study.
Takeaways:
- Enhanced Partnership: Revvity and Genomics England are expanding their collaboration to accelerate genomic initiatives across the UK, leveraging advanced laboratory capabilities and research expertise.
- Focus on Newborn Screening: The Generation Study aims to screen 100,000 newborns for 200 rare genetic conditions, utilizing Revvity’s DNA extraction technology to support early diagnosis and intervention.
- Regional Development: The partnership underscores a commitment to broadening the UK’s talent pool in molecular genomics, with a focus on Manchester as a hub for innovation.
Revvity, Inc. today announced an expansion of its work with Genomics England that leverages both organizations’ expertise and resources to advance critical genomic initiatives across the United Kingdom. Building on the parties’ long and productive work history, this advanced collaboration is dedicated to accelerating Genomics England’s renowned research programs, supporting diverse areas in genomics, and fostering talent in innovative healthcare fields.
“We’re grateful for the opportunity to expand our relationship with Genomics England to make a greater impact in saving the lives of babies with this new project,” says Madhuri Hegde, PhD, FACMG, Revvity’s senior vice president and chief scientific officer. “Additionally, the choice of Manchester reflects a deliberate commitment to broadening the UK’s talent base across the region and to help spread skills in clinical grade molecular genomics.”
Further Reading: Revvity Launches APOE Assay for Alzheimer’s Treatment Risk Assessment
The Generation Study
A cornerstone of the collaboration is the Generation Study, a world-leading study led by Genomics England, in partnership with the National Health Service, that aims to screen up to 100,000 newborns for 200 rare genetic conditions in England. In the study, which launched earlier this year, Revvity’s Omics laboratory in Manchester, UK will work with Genomics England to advance the early detection of genetic conditions in newborns. Utilizing the chemagic 360 instrument, Revvity’s team will extract DNA from cord blood samples collected from newborns across England.
“This partnership is an important contributor to our goal of researching earlier diagnosis and intervention for rare genetic conditions in newborns,” says Ellen Thomas, PhD, MD, chief medical officer at Genomics England. “By uniting Genomics England’s research expertise with Revvity’s advanced laboratory capabilities, we are proud to reinforce our commitment to advancing genomics research.”
